Soligenix to Speak at ACCESS CHINA Partnering Forum

Oct 10th, 2023 (Shanghai) — We are glad to announce that Dr. Christopher Schaber, the President & CEO of Soligenix, has been invited to present at ACCESS CHINA Partnering Forum on 14:15-14:30, October 16th, China time.

ACCESS CHINA Partnering Forum is the largest corporate access event between Asia and the western biopharma industry.

About the speaker

Christopher Schaber, Ph.D.

President & CEO of Soligenix

Christopher J. Schaber has over 30 years of experience in the pharmaceutical and biotechnology industry.

Dr. Schaber has been the President and Chief Executive Officer and a director since August 2006. He was appointed Chairman of the Board on October 8, 2009. He also serves on the board of directors of the Biotechnology Council of New Jersey (“BioNJ”) since January 2009 and the Alliance for Biosecurity since October 2014, and has been a member of the corporate councils of both the National Organization for Rare Diseases (“NORD”) and the American Society for Blood and Marrow Transplantation (“ASBMT”) since October 2009 and July 2009, respectively. Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, pre-clinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, Dr. Schaber was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories.

Dr. Schaber received his BA degree from Western Maryland College, his MS degree in Pharmaceutics from Temple University School of Pharmacy and his PhD degree in Pharmaceutical Sciences from the Union Graduate School.

About ACCESS CHINA Partnering Forum

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. We organize a series of online and in-person partnering events since 2019 with the mission to facilitate the collaboration between Western and Eastern biotechs.

This Autumn event, as part of our quarterly series, will feature 40+ leading pharmaceutical companies delivering virtual roadshows to an audience of 500+ participants online. During the event, audience can have access to innovative biopharmas and healthcare products from worldwide.

Event Name: ACCESS CHINA Partnering Forum-2023 Autumn

Date & Time: Oct. 16th-17th, 2023

Location: Zoom Webinar

Content: Keynote Speech, Company Showcase

Participants: Pharma/Biotech senior management and BDs.

View more information at https://biotochina.org/

关于药通中国交易合作论坛2023

“ACCESS CHINA 药通中国交易合作论坛2023”于2023年10月16日至17日线上举办。自2020年始，药通中国论坛系列活动已成功举办14届，成为了海内外生物医药、医疗器械企业寻找合作的领先跨境交易路演平台。这里聚集了海内外医药界顶尖BD和管理人员，为项目交流搭建了高效的沟通渠道，为资产交易创造了宝贵的机会。

大会名称：药通中国交易合作论坛2023

大会日期：2023.10.16-17（线上）

大会内容：主题演讲、海内外优质项目路演

参会观众：海内外医药企业（药企及Biotech）高管及BD、基金高管

查看更多信息： https://biotochina.org/